Back to News
Market Impact: 0.2
BioNTech SE and Bristol Myers Squibb Report Phase 2 Data for Pumitamig in Advanced NSCLC
Source: Nasdaq
Healthcare & Biotech
BioNTech and Bristol Myers Squibb announced the first data from the global Phase 2 ROSETTA Lung-107 trial, evaluating investigational pumitamig with docetaxel in patients with metastatic non-small cell lung cancer. The provided article text ends before reporting trial results, so efficacy, safety, and any market implications cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
BMY0.30
BNTX0.30
More News
- Iza-bren shows positive results in lung cancer trial
- BioNTech, DualityBio cancer drug trial meets primary endpoint
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma